{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-145434","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.341263+00:00","generated_at":"2026-06-01T09:19:20.442526+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tango Therapeutics discontinues TNG348 program due to liver toxicity in phase 1/2 trial","bullets":["Phase 1/2 trial of TNG348, a USP1 inhibitor, terminated because of Grade 3/4 liver function abnormalities in patients on study >8 weeks.","No patient had received TNG348 in combination with olaparib; single-agent toxicity drove decision.","Cash runway extended into 2027; PRMT5 (TNG908/TNG462) and CoREST programs remain on track with clinical update expected H2 2024.","CEO Barbara Weber cited patient safety as priority; stock may react to loss of pipeline candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-145434","json":"https://secwatch.observer/filing/0001193125-24-145434.json","markdown":"https://secwatch.observer/filing/0001193125-24-145434.md","text":"https://secwatch.observer/filing/0001193125-24-145434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312524145434/0001193125-24-145434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312524145434/d823505d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:19:20.442526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}